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Purpose: Sarpogrelate hydrochloride, a selective
5-hydroxytryptamine 2A antagonist, is a widely used
antiplatelet agent for the treatment of peripheral
arterial disease (PAD). DP-R202 is a new sarpogrelate
hydrochloride product with an improved dosage
regimen compared with the agent in current use. The
aim of this study was to compare the efﬁcacy andMarch 2016 557
Clinical Therapeuticssafety proﬁle of DP-R202 and Anplag* Tab in
patients with PAD.
Methods: This study was a 12-week, multicenter,
randomized, double-blinded, active-controlled, parallel
group comparative Phase III clinical trial. One hundred
ﬁfty-one volunteer patients with PAD were randomized to
receive DP-R202 300 mg once daily or Anplag Table 100
mg TID for 12 weeks. The primary end point was a
change in patient assessment of lower leg pain intensity
with the use of a visual analog scale (VAS) after 12 weeks
of treatment. Results after 4, 8, and 12 weeks of treatment
were compared with baseline and between treatment
groups, and all patients were assessed for adverse events
(AEs), clinical laboratory data, and vital signs.
Findings: Two hundred thirty-one patients from 25
medical centers were assessed, and 151 were enrolled
and randomly assigned to 1 of 2 treatment groups.
Seventy-ﬁve patients received DP-R202 300 mg once
daily and 76 patients received Anplag Table 100 mg
TID for 12 weeks. Analysis of the change in lower leg
pain intensity as determined by VAS score between
baseline and week 12 (mean [SD], 20.72 [20.06] mm
vs 15.55 [21.44] mm) suggested that DP-R202 was
not inferior to Anplag Tab, and no signiﬁcant differ-
ences were found in the secondary end points. No
signiﬁcant between-group differences were observed in
the prevalence of drug-related clinical- or laboratory-
determined AEs. For tolerability, no speciﬁc issue was
found during the treatment period.
Implication: The results of this study suggest that
DP-R202 was not inferior to Anplag Tab for efﬁcacy
in patients with PAD and indicated a good safety
proﬁle. (Clin Ther. 2016;38:557–573) & 2016 The
Authors. Published by Elsevier HS Journals, Inc.
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sarpogrelate.INTRODUCTION
Peripheral arterial disease (PAD) causes functional
and structural changes in blood vessels by hemadoste-
nosis due to atherosclerotic plaque.1,2 It occurs most
commonly in the descending aorta and lower artery,
although it can occur in all blood vessels except those
in in the heart and cerebrum.3 According to the US
National Health and Nutrition Examination Survey in*Trademark: Anplags Tab (Yuhan Corp, Seoul, Republic of
Korea).
5582000, the prevalence of PAD in adults older than 40
years is 4.3%, estimated to be 500,000 people, and
increases with age.4 PAD is largely classiﬁed into
asymptomatic, intermittent claudication, critical
lower limb ischemia, and acute lower limb ischemia
according to symptoms. PAD is a fatal disease that
results in reduced functionality and decreased quality
of life by causing fatigue, discomfort, and pain due to
occurrence of ischemia, accompanying chronic pain,
ulcer, or gangrene; PAD requires emergency treatment
such as amputation because of the rapid decrease in
limb perfusion.5,6 Therefore, treatment of PAD
decreases the mortality rate due to cardiovascular
disorders and reduces the symptoms and risk of lower
limb amputation in patients with symptoms of lower
limb ischemia.1 Sarpogrelate hydrochloride is a
selective 5-hydroxytryptamine 2A (serotonin) antago-
nist that blocks 5-hydroxytryptamine 2A receptors,
which are distributed in vascular cells and platelets,
and shows antithrombogenesis, antiplatelet aggrega-
tion, and cytostatic effects in vascular endothelial cells
carried by serotonin7,8 and is currently used in patients
to ameliorate the pain and symptoms of ulceration that
accompany chronic arterial occlusion. (Figure 1)
DP-R202 (sarpogrelate hydrochloride; 300 mg)
was developed to improve drug compliance over
sarpogrelate TID, because it includes both immediate-
and sustained-release components. Therefore, DP-
R202 has the advantage of showing both a rapid
onset of effect and sustained release.
In earlier bioequivalence and repeated dose tests
conducted on healthy male volunteers, when compar-
ing DP-R202 (300 mg, once daily) and Anplag* Tab
(100 mg, TID), the Cmax and Tmax values of sarpog-
relate and the M1 active metabolite were similar, and
the AUClast value was greater in the DP-R202 group
than in the Anplag Tab group. The antiplatelet
aggregation effect and residual platelet aggregation
did not differ signiﬁcantly between the groups.
For tolerability, serious adverse events (AEs) were
absent among the 34 patients administered DP-R202
or Anplag Tab; furthermore vital signs, ECG, and
physical examination indicated no meaningful
changes after administration. On the basis of these
results, the safety proﬁle and efﬁcacy of DP-R202 in
comparison with Anplag Tab in patients with PAD
were evaluated in a randomized, active-controlled,
and double-blind Phase III clinical study that involved
administration of the agents for 12 weeks.Volume 38 Number 3
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Figure 1. Flow diagram of all patients.
H.C. Lee et al.TARGET PATIENTS AND METHODS
Clinical Trial Design and Target Patients
This clinical trial was a 12-week, multicenter,
randomized, double-blind, parallel group, Phase III
study that enrolled patients in 25 institutions, ap-
pointed as national clinical trial institutions, and
received the approval of the institutional review
boards of all participating institutions.
Patients were men or women with lower limb
peripheral artery occlusion aged 420 years with
Fontaine stage II/III, who had lower limb pain or
symptoms such as leg stretching or numbing, whose
lower limb pain degree was 440 mm as evaluated by
visual analog scale (VAS) at screening, and with an
ankle-brachial index (ABI) r0.9 or stenosis rate
450%, diagnosed with PAD, and who voluntarily
agreed to participate and signed an informed consent
form. Patients who underwent peripheral-related sur-
gery within 1 month of study initiation, who were
Fontaine stage IV, New York Heart Association
class III–IV, had uncontrollable hypertension (systolicMarch 2016blood pressure,Z180 mm Hg, diastolic blood pressure,
Z110 mm Hg), a history of cerebrovascular disease
(cerebral infarction, cerebral hemorrhage, etc.) within 6
months before clinical trial participation, those with
uncontrollable diabetes (glycosylated hemoglobin
[HbA1c], Z9%), and renal insufﬁciency (creatinine,
43.0 mg/dL) were excluded from the trial.
Drugs that may affect the efﬁcacy of the investiga-
tional product, such as anticoagulants, antiplatelets,
thrombolytic agents, prostaglandin E1 preparations,
heparin, and aspirin 4100 mg/d, were prohibited
during the study period. In addition, NSAIDs and
analgesics were prohibited within 24 hours of the time
of efﬁcacy assessment. NSAID use during the study
period was not to exceed a total of 5 days.
Selected patients were stratiﬁed in a 1:1 ratio
and randomly assigned to receive the investigational
product or comparator according to their categorization
as Fontaine Stage II or III with the use of a block
randomization method. Both the investigators and
patients were blinded to the group assignment.559
Clinical TherapeuticsAdministration Method
The treatment drug was DP-R202 (sarpogrelate
hydrochloride 300 mg; Alvogen Korea Co., Ltd.,
Seoul, Republic of Korea) and the comparator was
Anplag Tab (sarpogrelate hydrochloride 100 mg;
Yuhan Corp, Seoul, Republic of Korea). Drugs were
administered for 12 weeks. The treatment group took
the investigational product of DP-R202, 1 tablet once
a day (morning), and took placebo, Anplag Tab, 1
tablet TID. The comparator group took the investiga-
tional product of Anplag Tab, 1 tablet TID, and took
placebo, DP-R202, 1 tablet once a day (morning). The
drugs were administered at a ﬁxed dosage; no dosage
ﬂuctuation according to subject condition was performed.
Clinical Trial Compliance
Drug compliance was calculated by checking the
quantity of investigational product returned by patients
at 2, 8, and 12 weeks. If drug compliance was o70%,
the subject was excluded according to the suspension
and dropout criteria in the clinical trial plan.
Efficacy and Safety Assessment Variables
Patients visited at 4, 8, and 12 weeks, including the
baseline visit (visit 2), for a total of 4 visits and
underwent efﬁcacy and quality-of-life assessments.
Variation in lower limb pain (by VAS) between
baseline and 12 weeks was the primary efﬁcacy
assessment variable. The variation in lower limb pain
(by VAS) and coldness (5-point scale) between base-
line and 4 and 8 weeks, ABI, ankle systolic pressure
(ASP), quality-of-life assessment index (Short Form
36; SF-36), maximum walking distance (MWD), pain-
free walking distance (PFWD), and investigator’s
general assessment (by VAS) at 4, 8, and 12 weeks
were the secondary efﬁcacy assessment variables. The
pain and coldness tests were performed by assessing
the pain and coldness felt by the subject 24 hours
before the visit. MWD and PFWD were measured
only in patients in whom such measurements were
possible, and they were asked to record the degree of
lower limb pain every day from baseline until the end
of the clinical trial. In addition, AEs, laboratory tests,
vital signs, and weight measurements were evaluated
for safety assessment. Physical tests and vital signs
were conducted at the screening visit, at the time of
initiation of administration of the investigational
product, and at 4, 8, and 12 weeks thereafter. A urine
pregnancy test and laboratory tests were conducted560at the screening visit and 12 weeks after the ﬁrst
administration of the investigational product. An ECG
test was conducted at the screening visit and at 4, 8,
and 12 weeks after the ﬁrst administration of the
investigational product. Hematologic, blood chemical,
blood coagulation, and urine tests were also performed.
Statistical Analysis
The per protocol set (PPS) was used as the main
analysis method, and the full analysis set (FAS) was
used as a secondary analysis of efﬁcacy data in this
clinical trial. Tolerability was analyzed with the use of
the safety set.
Efficacy Assessment
FAS analysis was conducted on patients who were
administered the investigational product at least once
and in whom the primary efﬁcacy assessment variable
was measured more than once after random assign-
ment. In the PPS analysis, data obtained from patients
who completed the clinical trial according to the
clinical trial protocol without any major violation
were included in the analysis. Those who took a
prohibited medication, had a rate of drug compliance
o70%, or in whom the primary efﬁcacy assessment
variable was not measured were excluded. The pri-
mary efﬁcacy assessment variable at baseline and 12
weeks, and the variation in lower limb pain (by VAS)
between baseline and 12 weeks are presented with the use
of descriptive statistics (number of patients, mean [SD],
and median) according to administration group. The
95% 2-sided CI of the variation between the 2 groups
was also presented. If the lower limit of the 2-sided 95%
CI was 4–10, the treatment drug was determined to be
noninferior to the comparator drug.
For the secondary efﬁcacy assessment, descriptive
statistics (number of patients, mean [SD], and median)
of each secondary efﬁcacy assessment variable are
presented, and the difference between the 2 groups
was analyzed with the use of a 2-sample t test or
Wilcoxon rank sum test according to whether the data
were normally distributed. The level of signiﬁcance of
all analyses was 0.05, and a 2-tailed test was con-
ducted. Continuous variables are presented as the
number of patients, means (SDs), and medians; cate-
gorical variables are presented as frequencies and
percentages. All P values are presented to 4 decimal
places, and a value of P o 0.05 was considered to
indicate statistical signiﬁcance. A test of normality wasVolume 38 Number 3
H.C. Lee et al.conducted on all continuous variables, and a 2-sample
t test, paired t test, Wilcoxon rank sum test, or
Wilcoxon signed rank test was conducted as appropri-
ate. For categorical variables, on the basis of expected
frequency being 45 in a section is 480%, either
Pearson χ2 test or Fisher exact test was performed.
Safety Assessment
The safety set comprised patients who were admin-
istered the investigational product at least once, and
the analysis was performed as described below.
AEs
Frequency and percentage of AEs after investiga-
tional product administration (treatment-emergent
AEs), adverse drug reactions (ADRs), serious AEs
(SAEs), and AEs that led to dropout were presented,
and the homogeneity between administration groups
was analyzed with the use of Pearson χ2 test or Fisher
exact test. AEs were coded according to system organ
class and preferred term in the Medical Dictionary for
Regulatory Activities, and number of occurrences,
occurrence rate, and number of occurrences by
administration group of coded AEs are also presented.
Laboratory Tests
For comparisons within groups, descriptive statistics
(number of patients, means [SDs], medians [range]) at
baseline, 12 weeks, and changes between baseline and
12 weeks are presented according to administration
group for continuous variables. A paired t test
or Wilcoxon signed rank test was conducted according
to whether the data were normally distributed. For
categorical variables, frequencies and percentages are
presented, and McNemar test was used for analysis.
For comparison between administration groups, a
2-sample t test or Wilcoxon rank sum test was used to
analyze changes from baseline to 12 weeks according
to whether the data were normally distributed for
continuous variables. For categorical variables, Pear-
son χ2 test or Fisher exact test was used to analyze the
rate of change from a normal baseline result to
abnormal at 12 weeks, and the homogeneity between
administration groups was determined.
Vital Signs and Weight
For comparison between administration groups,
descriptive statistics (number of patients, means
[SD], and medians [range]) at baseline and 12 weeks,March 2016and changes from baseline to 12 weeks are presented
according to administration group. A paired t test or
Wilcoxon signed rank test was performed according
to whether the data were normally distributed, and a
2-sample t test or Wilcoxon rank sum test was used to
analyze changes from baseline to 12 weeks according
to whether the data were normally distributed.RESULTS
A total of 151 patients who met the inclusion criteria were
enrolled in this trial (treatment group, 75 patients; com-
parator group, 76 patients). Of the 151 patients, 135
completed the trial (treatment group, 68 patients; com-
parator group, 67 patients). Sixteen patients (treatment
group, 7 patients; comparator group, 9 patients) termi-
nated the trial prematurely. The reasons for premature
termination were protocol deviation in 3 patients (com-
parator group), withdrawal of informed consent in
8 patients (treatment group, 5 patients; comparator
group, 3 patients), failure to follow-up in 1 subject
(comparator group), AEs in 3 patients (treatment group,
1 patient; comparator group, 2 patients), and other in 1
patient (treatment group). No subject dropped-out
because of lack of effectiveness. The demographic
information and other baseline information of the
patients were similar between the groups (Table I).
Efficacy Assessment
Assessment Result of Primary Efficacy Assessment
Variable
The difference in VAS scores between the 2 groups
before and after drug administration is shown in Table II.
Lower limb pain was measured with the use of a 100-
mm VAS, and the PPS analysis found that the mean VAS
change in lower limb pain from baseline to 12 weeks
(baseline–12 weeks) was 20.72 (20.06) mm in the treat-
ment group and 15.55 (21.44) mm in the comparator
group [95% 2-sided CI, –2.06 to 12.41). The lower limit
of the 2-sided CI was –2.06 mm, which exceeded the
noninferior limit (–10 mm); therefore, the noninferiority
of the treatment drug compared with the comparator
product was conﬁrmed.
Assessment Result of Secondary Efficacy Assessment
Variable
The secondary efﬁcacy assessment variable results
are presented in Tables III–IX. The mean lower limb
VAS scores (baseline–12 weeks) were decreased at561
Table I. Demographic and baseline characteristics.
Characteristic DP-R202 (n ¼ 75) Anplag (n ¼ 76) P
Age, mean [SD], y 70.20 [8.48] 68.92 [9.13] 0.4032*
Male, n (%) 67 (89.33) 62 (81.58) 0.1769†
Risk factor, n (%)
Hypertension 58 (77.33) 59 (77.63) 0.9650†
Dyslipidemia 39 (52.00) 37 (48.68) 0.6837†
Diabetes 40 (53.33) 32 (42.11) 0.1672†
Cardiovascular disease,‡ n (%) 41 (54.67) 32 (42.11) 0.1225†
Medication use, n (%)
Vasodilators 57 (76.00) 63 (82.89) 0.2943†
Antiplatelet agents and
anticoagulants
11 (14.67) 5 (6.58) 0.1064†
Statin 56 (74.67) 59 (77.63) 0.6690†
Fontaine classiﬁcation stage, n (%)
Stage II 65 (86.67) 59 (77.63) 0.1474†
Stage III 10 (13.33) 17 (22.37)
*Determined by Wilcoxon rank sum test.
†Determined by Pearson χ2 test.
‡Deﬁned as having myocardial infarction, angina, or coronary artery disease.
Clinical Therapeuticsbaseline compared with those at 4 and 8 weeks (treat-
ment group: 4 weeks, 8.68 [13.80] mm; 8 weeks,
15.62 [18.23] mm vs comparator group: 4 weeks,
8.58 [15.39] mm; 8 weeks, 12.36 [18.49] mm), and no
signiﬁcant difference was found between the groups
(P = 0.8820, P = 0.3817).
The mean change in ABI between baseline and at 4,
8, and 12 weeks was 0.01 (0.13), 0.01 (0.18), and
–0.01 (0.13), respectively, in the treatment group and
0.02 (0.11), 0.00 (0.09), and 0.01 (0.11), respectively,
in the comparator group. No signiﬁcant difference
was found between the groups (P = 0.7844, P =
0.6241, and P = 0.4609, respectively).
The coldness symptom score on a 5-point scale at
baseline compared with at 4, 8, and 12 weeks was
reduced by 0.20 (1.13), 0.35 (1.11), and 0.42 (1.30)
points, respectively, in the treatment group and by
0.45 (1.10), 0.64 (1.33), and 0.64 (1.26) points,
respectively, in the comparator group. No signiﬁcant
difference was found between the groups (P = 0.1187,
P = 0.1973, and P = 0.3311, respectively).
The mean change in ASP at baseline compared with
at 4, 8, and 12 weeks was –0.60 (23.49), 1.45 (29.01),562and –0.70 (24.03) mm Hg, respectively, in the treat-
ment group and 0.56 (19.61), –2.11 (16.97), and
–1.53 (20.87) mm Hg, respectively, in the comparator
group. No statistically signiﬁcant difference was found
between the groups (P = 0.9185, P = 0.7517, and P =
0.6790, respectively).
The change in MWD at baseline compared with
at 12 weeks was 43.10 (162.92) m in the treatment
group and 38.93 (154.97) m in the comparator
group. The PFWD was increased to 52.13 (176.06)
m in the treatment group and 17.09 (143.39) m in
the comparator group, respectively, at 12 weeks
compared with baseline. The between-group differ-
ence was not signiﬁcant (P = 0.4279 and P =
0.2871, respectively). The MWD and PFWD found
signiﬁcant differences compared with baseline in
the treatment group but not the in comparator
group.
The mean general condition of patients assessed by
an investigator with the use of a VAS at 4, 8, and 12
weeks was decreased to 11.66 (14.40), 18.45 (17.32),
and 21.72 (18.75) mm, respectively, in the treatment
group and 10.84 (14.46), 14.28 (16.26), and 18.27Volume 38 Number 3
Table II. Changes in VAS of lower leg pain after 12 weeks of treatment.
Pain VAS, mm DP-R202 Anplag
Mean difference
between groups [95% CI] P
PPS, n 65 64
Baseline 0.3374*
Mean [SD] 61.89 [15.44] 64.25 [15.38]
Median 60.00 61.00
Min, Max 40.00, 100.00 40.00, 100.00
Week 12
Mean [SD] 41.17 [19.87] 48.70 [19.36]
Median 40.00 50.00
Min, Max 10.00, 95.00 11.00, 95.00
Change (week 12–baseline) 5.18 [–2.06 to 12.41] 0.1592†
Mean [SD] 20.72 [20.06] 15.55 [21.44]
Median 20.00 10.00
Min, Max –20.00, 70.00 –35.00, 70.00
P o0.0001†,‡ o0.0001†,‡
FAS, n 74 72
Baseline
Mean [SD] 61.15 [15.54] 64.26 [15.30] 0.1809*
Median 60.00 61.00
Min, Max 40.00, 100.00 40.00, 100.00
Week 12
Mean [SD] 42.32 [19.39] 48.90 [19.30]
Median 40.00 50.00
Min, Max 10.00, 95.00 10.00, 95.00
Change (week 12–baseline) 3.46 [–3.36 to 10.29] 0.3175†
Mean [SD] 18.82 [19.71] 15.36 [21.98]
Median 19.50 10.00 10.00
Min, Max –20.00, 70.00 –35.00, 70.00
P o0.0001†,‡ o0.0001†,‡
FAS = full analysis set; PPS = per protocol set; VAS = visual analog scale.
*Determined by Wilcoxon rank sum test.
†Determined by 2-sample t test.
‡Determined by paired t test.
H.C. Lee et al.(18.98) mm, respectively, in the comparator group.
No statistically signiﬁcant difference was found
between the groups (P = 0.6107, P = 0.2359, and
P = 0.2999, respectively).
For quality of life assessed with the use of the
SF-36, no statistically signiﬁcant difference between
the groups was observed. FAS analysis found a similar
result as PPS, and no statistically signiﬁcant difference
was found between the groups.March 2016Final Conclusion on Efficacy
The noninferiority of the study group compared with
the comparator group was conﬁrmed by the improve-
ment in lower limb pain with the use of a VAS in patients
with PAD of Fontaine stage II/III accompanied by
claudication and lower limb pain at rest. No signiﬁcant
difference was found between the groups in terms of
coldness, ABI, ASP, quality of life (SF-36), MWD, PFWD,
or general assessment performed by an investigator.563
Table III. Changes in VAS of lower leg pain after 4 and 8 weeks of treatment.
Pain VAS, mm
PPS FAS
DP-R202 Anplag P DP-R202 Anplag P
Baseline, n 65 64 0.3374* 74 72 0.1809*
Mean [SD] 61.89 [15.44] 64.25 [15.38] 61.15 [15.54] 64.26 [15.30]
Median 60.00 61.00 60.00 61.00
Min, Max 40.00, 100.00 40.00, 100.00 40.00, 100.00 40.00, 100.00
Week 4
Mean [SD] 53.22 [16.79] 55.67 [17.70] 53.05 [16.57] 55.57 [17.75]
Median 50.00 55.00 50.00 55.00
Min, Max 18.00, 97.00 21.00, 90.00 18.00, 97.00 20.00, 90.00
Change 1 0.8820* 0.3175†
Mean [SD] 8.68 [13.80] 8.58 [15.39] 8.09 [13.24] 18.69 [16.00]
Median 10.00 5.00 8.00 5.00
Min, Max –20.00, 60.00 –25.00, 51.00 –20.00, 60.00 –25.00, 51.00
P o0.0001‡ o0.0001§ o0.0001‡ o0.0001‡
Week 8
Mean [SD] 46.28 [18.63] 51.89 [18.89] 46.82 [18.08] 51.90 [18.93]
Median 47.00 50.00 47.00 50.00
Min, Max 0.00, 90.00 20.00, 90.00 0.00, 90.00 10.00, 90.00
Change 2 0.3817* 0.5429*
Mean [SD] 15.62 [18.23] 12.36 [18.49] 14.32 [17.67] 12.36 [19.57]
Median 15.00 8.00 10.50 7.50
Min, Max –20.00, 60.00 –21.00, 69.00 –20.00, 60.00 –21.00, 69.00
P o0.0001§ o0.0001‡ o0.0001‡ o0.0001‡
Change 1 ¼ baseline–week 4; Change 2 ¼ baseline–week 8; FAS ¼ full analysis set; PPS ¼ per protocol set; VAS ¼ visual
analog scale.
*Determined by Wilcoxon rank sum test.
†Determined by 2-sample t test.
‡Determined by Wilcoxon signed rank test.
§Determined by paired t test.
Clinical TherapeuticsSafety Assessment
Summary of AEs
The frequency of AEs after investigational product
administration was 29.73% (22 of 74 patients,
41 cases) in the treatment group, and 40.00% (30 of
75 patients, 49 cases) in the comparator group. The
ADR rates in the study and comparator groups were
1.35% (1 of 74 patients, 1 case) and 4.00% (3 of 75
patients, 3 cases), respectively. The SAE rate was
1.35% (1 of 74 patients, 1 cases) and 5.33% (4 of
75 patients, 4 cases) in the study and comparator
groups, respectively. The rate of AEs that led to
dropout was 2.67% (2 of 75 patients, 2 cases) in the564comparator group, and 0.00% (0 of 74 patients,
0 cases) in the treatment group. Therefore, none
of the criteria differed signiﬁcantly between the
groups.
Severity of AEs and Cause-and-Effect Relation with
the Drug
The severity of AEs and their association with the
investigational product were summarized. Events
evaluated to be “cannot exclude relevant possibility
(possible), high relevant possibility (probable), def-
initely relevant (deﬁnite)” by an investigator were
classiﬁed as drug-related AEs (ADRs. AEs assessedVolume 38 Number 3
Table IV. Changes in ABI after 4, 8, and 12 weeks of treatment.
ABI
PPS FAS
DP-R202 Anplag P DP-R202 Anplag P
Screening, n 65 64 0.4466* 74 72 0.4522*
Mean [SD] 0.68 [0.15] 0.70 [0.12] 0.68 [0.15] 0.70 [0.12]
Median 0.70 0.72 0.70 0.72
Min, Max 0.24, 0.89 0.40, 0.882 0.24, 0.89 0.40, 0.88
Week 4, n 65 63 73 70
Mean [SD] 0.69 [0.16] 0.73 [0.15] 0.70 [0.16] 0.73 [0.15]
Median 0.66 0.72 0.66 0.72
Min, Max 0.28, 1.18 0.44, 1.20 0.28, 1.18 0.44, 1.20
Change 1, n 65 63 0.7844* 73 70 0.6214*
Mean [SD] 0.01 [0.13] 0.02 [0.11] 0.01 [0.13] 0.02 [0.11]
Median 0.01 0.00 0.01 0.00
Min, Max –0.25, 0.68 –0.15, 0.41 –0.25, 0.68 –0.15, 0.41
P 0.8657† 0.5973† 0.8538† 0.3941†
Week 8, n 65 63 73 70
Mean [SD] 0.69 [0.17] 0.71 [0.15] 0.70 [0.17] 0.71 [0.16]
Median 0.68 0.71 0.68 0.717
Min, Max 0.21, 1.40 0.37, 1.05 0.21, 1.40 –0.23, 0.48
Change 2 65 63 0.6241* 73 70 0.7017*
Mean [SD] 0.01 [0.18] 0.00 [0.09] 0.01 [0.17] 0.01 [0.11]
Median 0.00 0.00 0.00 0.01
Min, Max –0.22, 1.16 0.28, –0.23 –0.22, 1.16 –0.23, 0.48
P 0.5786† 0.9026‡ 0.7604† 0.8988†
Week 12, n 63 63 73 70
Mean [SD] 0.68 [0.15] 0.72 [0.14] 0.70 [0.17] 0.73 [0.15]
Median 0.69 0.7 0.70 0.73
Min, Max 0.29, 1.01 0.34, 1.16 0.29, 1.40 0.34, 1.24
Change 3, n 63 63 0.4609* 73 70 0.5617*
Mean [SD] –0.01 [0.13] 0.01 [0.11] 0.01 [0.19] 0.02 [0.12]
Median –0.01 0.00 –0.01 0.00
Min, Max –0.36, 0.35 –0.30, 0.29 –0.36, 1.16 –0.30, 0.48
P o0.5626‡ 0.8335† 0.9390† 0.6299†
ABI ¼ ankle-brachial index; Change 1 ¼ week 4–screening; Change 2 ¼ week 8–screening; Change 2 ¼ week 12–screening;
FAS ¼ full analysis set; PPS ¼ per protocol set.
*Determined by Wilcoxon rank sum test.
†Determined by Wilcoxon signed rank test.
‡Determined by paired t test.
H.C. Lee et al.as “not related, or high probability of no relevancy
(unlikely)” were classiﬁed as non–drug-related AEs
(not ADRs). AEs in the treatment group were
mostly mild (92.68%, 38 cases); no severe AE wasMarch 2016detected. Most cases in the comparator group were
also mild (85.71%, 42 cases), only a single severe
AE was detected (2.04%, 1 case). Among these,
1 mild ADR occurred in the treatment group565
Table V. Changes in coldness 5-point scale after 4, 8, and 12 weeks of treatment.
Coldness 5-point scale
PPS FAS
DP-R202 Anplag P DP-R202 Anplag P
Baseline, n 65 64 0.4250* 74 72 0.3143*
Mean [SD] 2.55 [1.29] 2.75 [1.30] 2.57 [1.29] 2.79 [1.32]
Median 3.00 3.00 3.00 3.00
Min, Max 1.00, 5.00 1.00, 5.00 1.00, 5.00 1.00, 5.00
Week 4, n 64 64 73 72
Mean [SD] 2.34 [1.30] 2.30 [1.15] 2.38 [1.31] 2.35 [1.20]
Median 2.00 2.00 2.00 2.50
Min, Max 1.00, 5.00 1.00, 5.00 1.00, 5.00 1.00, 5.00
Change, n 64 64 0.1187* 73 72 0.0898*
Mean [SD] –0.20 [1.13] –0.45 [1.10] 0.18 [1.10] –0.44 [1.06]
Median 0.00 0.00 0.00 0.00
Min, Max –3.00, 3.00 –4.00, 2.00 –3.00, 3.00– 4.00, 2.00
P 0.1335† o0.0010† 0.1578† 0.0004†
Week 8, n 65 64 74 72
Mean [SD] 2.20 [1.16] 2.11 [1.17] 2.26 [1.19] 2.18 [1.23]
Median 2.00 2.00 2.00 2.00
Min, Max 1.00, 4.00 1.00, 5.00 1.00, 5.00 1.00, 5.00
Change, n 65 64 0.1973* 74 72 0.1516*
Mean [SD] –0.35 [1.11] –0.64 [1.33] –0.31 [1.08] –0.61 [1.28]
Median 0.00 0.00 0.00 0.00
Min, Max –3.00, 3.00 –4.00, 3.00 –3.00, 3.00 –4.00, 3.00
P 0.0077† o0.0001† 0.0123† o0.0001†
Week 12, n 65 64 74 72
Mean [SD] 2.14 [1.16] 2.11 [1.24] 2.20 [1.19] 2.17 [1.27]
Median 2.00 2.00 2.00 2.00
Min, Max 1.00, 5.00 1.00, 5.00 1.00, 5.00 1.00, 5.00
Change, n 65 64 0.3311* 74 72 0.2168*
Mean [SD] –0.42 [1.30] –0.64 [1.26] –0.36 [1.26] –0.63 [1.22]
Median 0.00 0.00 0.00 0.00
Min, Max –4.00, 3.00 –4.00, 2.00 –4.00, 3.00 –4.00, 2.00
P o0.0001‡ o0.0001† 0.0153† o0.0001†
Change 1 ¼ week 4–baseline; Change 2 ¼ week 8–baseline; Change 2 ¼ week 12–baseline; FAS ¼ full analysis set; PPS ¼ per
protocol set.
*Determined by Wilcoxon rank sum test.
†Determined by Wilcoxon signed rank test.
‡Determined by paired t test.
Clinical Therapeutics(2.44%) and 2 ADRs, comprising 1 mild (2.04%)
and 2 moderate ADRs, occurred in the comparator
group (4.08%). No severe ADR occurred in either
group.566AEs According to Organ System
The adverse event rate and number of events
per organ system after drug administration are pre-
sented in Table X. The proportion of patients whoVolume 38 Number 3
Table VI. Changes in ASP after 4, 8, and 12 weeks of treatment.
ASP, mm Hg
PPS FAS
DP-R202 Anplag P DP-R202 Anplag P
Baseline, n 65 64 0.0862* 74 72 0.0899*
Mean [SD] 92.52 [22.74] 98.94 [19.21] 92.41 [23.27] 98.40 [18.88]
Median 95.00 99.50 99.50 99.00
Min, Max 39.00, 150.00 57.00, 134.00 39.00, 150.00 57.00, 134.00
Week 4, n 65 63 73 70
Mean [SD] 91.92 [23.16] 100.06 [23.79] 93.42 [24.21] 101.06 [23.97]
Median 87.00 98.00 87.00 99.00
Min, Max 31.00, 143.00 56.00, 184.00 31.00, 150.00 56.00, 184.00
Change, n 65 63 73 70
Mean [SD] 91.92 [23.16] 100.06 [23.79] 93.42 [24.21] 101.06 [23.97]
Median 87.00 98.00 87.00 99.00
Min, Max 31.00, 143.00 56.00, 184.00 31.00, 150.00 56.00, 184.00
P 0.8375† 0.6092‡ 0.8741† 0.8845‡
Week 8, n 65 63 73 70
Mean [SD] 93.97 [26.26] 97.40 [22.90] 95.79 [27.06] 98.20 [23.54]
Median 92.00 96.00 93.00 96.00
Min, Max 26.00, 193.00 44.00, 150.00 26.00, 193.00 44.00, 150.00
Change, n 65 63 0.7517§ 73 70 0.4795§
Mean [SD] 1.45 [29.01] –2.11 [16.97] 2.79 [28.37] –0.87 [19.61]
Median 2.00 –4.00 3.00 –3.50
Min, Max –63.00, 154.00 –39.00, 50.00 –63.00, 154.00 –39.00, 71.00
P 0.7836‡ 0.3273† 0.7771‡ 0.3703‡
Week 12, n 63 63 73 70
Mean [SD] 93.30 [22.62] 97.98 [22.70] 96.33 [25.59] 99.09 [23.85]
Median 93.00 97.00 94.00 96.50
Min, Max 36.00, 144.00 52.00, 185.00 36.00, 193.00 52.00, 185.00
Change, n 63 63 0.6790§ 73 70 0.3400§
Mean [SD] –0.70 [24.00] –1.53 [20.87] 3.33 [29.65] 0.02 [23.06]
Median 2.00 –4.00 3.00 –3.50
Min, Max –58.00, 51.00 –53.00, 86.00 –58.00, 154.00 –53.00, 86.00
P 0.8183† 0.2545‡ 0.5219‡ 0.3869‡
ASP ¼ ankle systolic pressure; Change 1 ¼ week 4–baseline; Change 2 ¼ week 8–baseline; Change 3 ¼ week 12–baseline;
FAS ¼ full analysis set; PPS ¼ per protocol set.
*Determined by 2-sample t test.
†Determined by paired t test.
‡Determined by Wilcoxon signed rank test.
§Determined by Wilcoxon rank sum test.
H.C. Lee et al.experienced AEs after investigational product
administration was 29.73% (22 of 74 patients,
41 cases) in the treatment group, and 40.00% (30 of
75 patients, 49 cases) in the comparator group.March 2016Infections and infestations exhibited the highest
occurrence rate in both groups when AEs were
classiﬁed into system organ class and preferred term
of Medical Dictionary for Regulatory Activities567
Table VII. Changes in MWD after 12 weeks of treatment.
MWD, m
PPS FAS
DP-R202 Anplag P DP-R202 Anplag P
Baseline, n 65 64 0.2012* 74 72 0.1339*
Mean [SD] 313.90 [245.30] 394.15 [286.17] 309.12 [242.29] 388.62 [279.64]
Median 222.00 302.00 222.00 302.00
Min, Max 40.00, 800.00 18.00, 800.00 40.00, 800.00 18.00, 800.00
Week 12, n 48 44 52 48
Mean [SD] 360.08 [273.93] 435.75 [300.05] 348.62 [269.53] 426.75 [299.54]
Median 252.00 352.50 240.00 328.00
Min, Max 48.00, 800.00 24.00, 804.00 48.00, 800.00 24.00, 804.00
Change, n 48 44 0.4279* 52 48 0.2782*
Mean [SD] 43.10 [162.92] 38.93 [154.97] 40.62 [157.92] 29.88 [152.25]
Median 12.00 0.00 12.00
Min, Max –447.00, 444.00 –420.00, 534.00 –447.00, 444.00 –420.00, 534.00
P 0.0162† 0.0801† 0.0200† 0.2405†
Change ¼ week 12–baseline; FAS ¼ full analysis set; MWD ¼ maximum walking distance; PPS ¼ per protocol set.
*Determined by Wilcoxon rank sum test.
†Determined by Wilcoxon signed rank test.
Table VIII. Changes in PFWD after 12 weeks of treatment.
PFWD, m
PPS FAS
DP-R202 Anplag P DP-R202 Anplag P
Baseline, n 50 46 0.1268* 56 51 0.1058*
Mean [SD] 143.63 [140.73] 178.69 [149.39] 141.11 [135.81] 174.18 [144.12]
Median 96.50 130.00 96.50 136.00
Min, Max 20.00, 800.00 26.66, 725.00 20.00, 800.00 26.66, 725.00
Week 12, n 47 44 51 47
Mean [SD] 185.74 [168.46] 194.43 [179.34] 180.53 [163.81] 190.89 [175.22]
Median 120.00 142.00 120.00 135.00
Min, Max 31.00, 800.00 8.00, 800.00 31.00, 800.00 8.00, 800.00
Change, n 45 44 0.2871* 49 47 0.2791*
Mean [SD] 52.13 [176.06] 17.09 [143.39] 50.16 [169.34] 14.85 [141.49]
Median 29.00 8.50 19.00 9.00
Min, Max –480.00,708.00 –420.00, 569.00 –480.00, 708.00 –420.00, 569.00
P 0.0056† 0.2673† 0.0035† 0.2710†
Change ¼ week 12–baseline; FAS ¼ full analysis set; PFWD ¼ pain-free walking distance; PPS ¼ per protocol set.
*Determined by Wilcoxon rank sum test.
†Determined by Wilcoxon signed rank test.
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Table IX. Changes in VAS assessed by investigator after 4, 8, and 12 weeks of treatment.
VAS
PPS FAS
DP-R202 Anplag P DP-R202 Anplag P
Baseline, n 65 64 0.4266* 74 72 0.3201*
Mean [SD] 61.89 [15.49] 62.86 [13.10] 61.35 [15.18] 62.69 [12.75]
Median 60.00 60.00 60.00 60.00
Min, Max 40.00, 100.00 40.00, 92.00 40.00, 100.00 40.00, 92.00
Week 4, n 65 64 74 72
Mean [SD] 50.02 [16.01] 52.02 [17.32] 50.50 [15.95] 52.54 [17.72]
Median 50.00 50.00 50.00 50.00
Min, Max 10.00, 85.00 6.00, 90.00 10.00, 85.00 6.00, 90.00
Change 1, n 65 64 0.6107* 74 72 0.6656*
Mean [SD] –11.66 [14.40] –10.84 [14.46] –10.85 [13.97] –10.15 [15.94]
Median –10.00 –7.50 –10.00 –6.00
Min, Max –60.00, 22.00 –55.00, 6.00 –60.00, 22.00 –55.00, 30.00
P o0.0001† o0.0001† o0.0001† o0.0001†
Week 8, n 65 64 74 72
Mean [SD] 43.23 [17.27] 48.58 [18.21] 44.39 [17.10] 49.03 [18.58]
Median 45.00 46.00 46.00 49.00
Min, Max 0.00, 86.00 16.00, 89.00 0.00, 86.00 10.00, 90.00
Change 2, n 65 64 0.2359* 74 72 0.3447*
Mean [SD] –18.45 [17.32] –14.28 [16.26] –16.96 [17.04] –13.67 [17.40]
Median –15.00 –10.00 –15.00 –10.00
Min, Max –70.00, 11.00 –65.00, 15.00 –70.00, 11.00 –65.00, 30.00
P o0.0001† o0.0001† o0.0001† o0.0001†
Week 12, n 65 64 74 72
Mean [SD] 39.95 [19.66] 44.59 [19.08] 41.51 [19.44] 45.49 [19.43]
Median 40.00 40.00 40.00 40.00
Min, Max 0.00, 90.00 10.00, 90.00 0.00, 90.00 10.00, 90.00
Change 3, n 65 64 0.2999‡ 74 72 0.4102‡
Mean [SD] –21.72 [18.75] –18.27 [18.98] –19.84 [18.58] –17.21 [19.88]
Median –20.00 –17.00 –20.00 –15.50
Min, Max –70.00, 19.00 –65.00, 20.00 –70.00, 19.00 –65.00, 30.00
P o0.0001§ o0.0001§ o0.0001§ o0.0001§
ASP ¼ ankle systolic pressure; Change 1 ¼ week 4–baseline; Change 2 ¼ week 8–baseline; Change 3 ¼ week 12–baseline;
FAS ¼ full analysis set; PPS ¼ per protocol set; VAS ¼ visual analog scale.
*Determined by Wilcoxon rank sum test.
†Determined by Wilcoxon signed rank test.
‡Determined by 2-sample t test.
§Determined by paired t test.
H.C. Lee et al.version 17.0. Other AEs occurred in45% of patients;
these were gastrointestinal disorders and metabolism
and nutrition disorders in the treatment group, andMarch 2016metabolism and nutrition disorders, general disorders,
administration site conditions, and abnormal test
values (investigations) in the comparator group.569
Table X. Incidence rate and number of AEs reported (treatment-emergent AE, safety set).
System Organ Class/Preferred
Term
DP-R202
(n ¼ 74)
Anplag
(n ¼ 75)
Total
(n ¼ 149)
n (%)
AEs
Reported,
n n (%)
AEs
Reported,
n n (%)
AEs
reported,
n
Infections and infestations 8 (10.81) 12 10 (13.33) 12 18 (12.08) 24
Gastrointestinal disorders 4 (5.41) 9 5 (6.67) 6 9 (6.04) 15
General disorders and
administration site conditions
2 (2.70) 3 4 (5.33) 5 6 (4.03) 8
Investigations 1 (1.35) 1 5 (6.67) 5 6 (4.03) 6
Metabolism and nutrition disorders 4 (5.41) 5 1 (1.33) 1 5 (3.36) 6
Musculoskeletal and connective
tissue disorders
2 (2.70) 2 3 (4.00) 3 5 (3.36) 5
Nervous system disorders 2 (2.70) 2 2 (2.67) 3 4 (2.68) 5
Respiratory, thoracic and
mediastinal disorders
1 (1.35) 1 3 (4.00) 3 4 (2.68) 4
Skin and subcutaneous tissue
disorders
1 (1.35) 1 3 (4.00) 3 4 (2.68) 4
Vascular disorders 1 (1.35) 1 2 (2.67) 2 3 (2.01) 3
Injury, poisoning and procedural
complications
1 (1.35) 1 1 (1.33) 1 2 (1.34) 2
Blood and lymphatic system
disorders
0 (0.00) 0 1 (1.33) 1 1 (0.67) 1
Cardiac disorders 1 (1.35) 1 0 (0.00) 0 1 (0.67) 1
Hepatobiliary disorders 0 (0.00) 0 1 (1.33) 1 1 (0.67) 1
Neoplasms benign, malignant
and unspeciﬁed (including
cysts and polyps)
0 (0.00) 0 1 (1.33) 1 1 (0.67) 1
Psychiatric disorders 1 (1.35) 1 0 (0.00) 0 1 (0.67) 1
Renal and urinary disorders 1 (1.35) 1 0 (0.00) 0 1 (0.67) 1
Reproductive system and
breast disorders
0 (0.00) 0 1 (1.33) 1 1 (0.67) 1
Surgical and medical procedures 0 (0.00) 0 1 (1.33) 1 1 (0.67) 1
AE ¼ adverse event.
Clinical TherapeuticsADRs According to Organ System
The proportion of patients who experienced ADRs
in the treatment group and comparator group was
1.35% (1 of 74 patients, 1 case) and 4.00% (3 of 75
patients, 3 cases), respectively. One case of urticaria
occurred in the treatment group and 1 case each of
pruritus, arthralgia, and dyspnea exertional occurred
in the comparator group.570AEs That Led to Dropout
Two patients in the comparator group dropped out
of the study because of AEs; pruritus was conﬁrmed as
the ADR.
SAEs and Other Important AEs
The proportion of patients who experienced SAEs
was 1.35% (1 of 74 patients, 1 case) in the treatmentVolume 38 Number 3
H.C. Lee et al.group and 5.33% (4 of 75 patients, 4 cases) in the
comparator group. One case of atrial ﬁbrillation
occurred in the treatment group and 1 case each of
shock, thromboangiitis obliterans, infectious colitis,
and hyponatremia occurred in the comparator group.
Serious ADRs were absent in both groups.
Laboratory Tests
For changes in hematologic variables between base-
line and 12 weeks, signiﬁcant reductions in hemoglobin
and hematocrit were found in the comparator group,
but no statistically signiﬁcant difference was found
between the groups. All other criteria exhibited no
signiﬁcant differences within or between the groups.
Sodium, HDL-C, ALP, and HbA1c exhibited signiﬁ-
cant differences between screening and 12 weeks in the
comparator group, and none in the treatment group.
Among these, the difference in HbA1c between screen-
ing and 12 weeks was –0.05% (0.50%) in the treatment
group and 0.14% (0.42%) in the comparator group;
the difference was statistically signiﬁcant (P ¼ 0.0048).
No other criteria exhibited statistically signiﬁcant differ-
ences between the groups.
Results of blood coagulation and urine tests indi-
cated no signiﬁcant differences between and screening
and 12 weeks in either the study or comparator group.
Vital Signs and Weight
Vital signs and weight did not differ signiﬁcantly
between screening and 12 weeks in the comparator and
treatment groups. Moreover, no signiﬁcant difference
was found in vital signs and weight between the groups.
Final Conclusion on Safety Profile
The safety proﬁle was evaluated on the basis
of AEs, laboratory tests, vital signs, and weight
(treatment group, 74 patients; comparator group,
75 patients). The AE rate after the investigational
product administration was 29.73% (22 of 74 pa-
tients, 41 cases) in the treatment group and 40.00%
(30 of 75 patients, 3 cases, 49 cases) in the compara-
tor group. The ADR rate was 1.35% (1 of 74 patients,
1 case) in the treatment group and 4.00% (3 of 75
patients, 3 cases) in the comparator group. Most AEs
were mild (treatment group, 92.68%, 38 cases vs
comparator group, 85.71%, 42 cases), and no severe
ADRs occurred in either group. The SAE rate was
1.35% (1 of 74 patients, 1 case) in the treatment
group and 5.33% (4 of 75 patients, 4 cases) in theMarch 2016comparator group; no serious ADR was detected. In
addition, AEs leading to dropout were absent in the
treatment group; however, 2 cases occurred in the
comparator group. One case was conﬁrmed to be an
ADR. For vital signs and weight, changes were found
between baseline and 12 weeks, and no tendency to
violate the safety proﬁle in terms of the extent of
changes was observed. In addition, the change in
HbA1c between baseline and 12 weeks was –0.05%
(0.50%) in the treatment group and 0.14% (0.42%)
in the comparator group; the difference was signiﬁcant
(P ¼ 0.0048). However, no signiﬁcant difference was
found between the groups in the normal/abnormal
rate (P ¼ 0.1445), and no tendency to violate the
safety proﬁle was observed. In the normal/abnormal
analysis, no other laboratory test variable differed
signiﬁcantly between the groups. There was no sig-
niﬁcant difference in safety proﬁle in treatment group
compared to comparator group.CONSIDERATIONS AND GENERAL
CONCLUSION
This clinical trial was a 12-week, multicenter, random-
ized, double-blind, parallel-group, Phase III study that
enrolled patients in 25 institutions appointed as national
clinical trial institutions and that received the approval
of all the institutional review boards.
This clinical study aimed to ﬁnd the noninferiority
of DP-R202 compared with Anplag Tab by assessing
their efﬁcacy (in terms of reduction in lower limb
pain) and the safety proﬁle after 12 weeks of admin-
istration in patients with chronic arterial occlusion.
Of the participants in this study, 60 to 70 were men,
and a high proportion had Fontaine stage II; however,
several patients with stage III were also included. The
demographic characteristics and severity characteristics
of patients were similar in the 2 groups.
Lower limb pain in both groups improved signiﬁ-
cantly between baseline and 12 weeks as assessed by
the change in VAS (change in VAS: treatment group,
20.72 [20.06] mm vs comparator group, 15.55
[21.44] mm); therefore, DP-R202 was shown to be
noninferior to Anplag Tab. This is in agreement with
a previous report of the efﬁcacy of inositol nicotinate
(Hexopal†) another peripheral vasodilator (inositol vs
placebo, 19.9 mm vs 8.8 mm; P ¼ 0.005).9 Pain
reduction was deﬁned as an improvement in
claudication distance and increases in MWD and571
Clinical TherapeuticsPFWD between baseline and 12 weeks. In both
groups, the pain VAS score decreased with
increasing treatment duration.
Among secondary efﬁcacy assessment variables, the
coldness symptom decreased gradually over time in
both groups, therefore conﬁrming the effect of sar-
pogrelate in improving ischemic symptoms, and no
signiﬁcant difference was found between the groups.
For ABI and ASP, modality of change at 4, 8, and
12 weeks was inconsistent, and no signiﬁcant im-
provement was found in either group. This result is
also in agreement with the above-mentioned previous
report.10 MWD and PFWD increased between
baseline and 12 weeks, and no statistically signi-
ﬁcant difference was found between the groups. In
the general assessment performed by an investigator
with the use of a VAS, both groups reported gradual
improvements over time, and no statistically signi-
ﬁcant difference was found between the groups. On
quality-of-life assessment (SF-36) in terms of the
bodily pain and PCS criteria, both groups reported
improvements between baseline and at 4, 8, and
12 weeks, and no criterion differed signiﬁcantly
between the groups. However, MWD and PFWD
show signiﬁcant difference from baseline in the
DP-R202–administered group, unlike the Anplag
Tab–administered group.
For tolerability, the AE, ADR, and SAE rates were
lower in the treatment group than in the comparator
group. No subject experienced a severe ADR, suggest-
ing that DP-R202 has equal or superior safety than
Anplag Tab. In terms of laboratory test results, the
increase in HbA1c between baseline and 12 weeks
was signiﬁcantly greater in the treatment group than
in the comparator group (treatment group vs compa-
rator group, –0.05% [0.50%] vs 0.14% [0.42%]; P ¼
0.0048). However, this was not considered clinically
meaningful because the change was within the normal
range. No signiﬁcant difference was found between
the groups in other laboratory test results and vital
signs. Therefore, once daily administration of DP-
R202 (sarpogrelate 300 mg) to patients with periph-
eral arterial occlusive disease with Fontaine stage II/III
accompanied by claudication or lower limb pain at
rest was found to be noninferior to TID administra-
tion of Anplag Tab in terms of improvement of lower
limb pain; moreover, the 2 regimens exhibited equiv-
alent tolerability. In conclusion, DP-R202 improved
symptoms and the drug compliance rate in patients572with peripheral arterial occlusive disease who require
long-term administration.
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